Valproic Acid
- TRADE NAMES: Depacon (AbbVie); Depakene (AbbVie); Depakote (AbbVie)
- INDICATIONS: Seizures, migraine
- SYNONYM: valproate sodium; divalproex
- CLASS: Anticonvulsant, Antipsychotic, Mood stabilizer
- HALF-LIFE: 6–16 hours
Amitriptyline, Aspirin, Ceftobiprole, Cholestyramine, Clobazam, Clozapine, Doripenem, Eslicarbazepine, Ethosuximide, Imipenem/Cilastatin/Relebactam, Indinavir, Ivermectin, Lesinurad, Levomepromazine, Lumateperone, Meropenem, Meropenem & Vaborbactam, Olanzapine, Oxcarbazepine, Paliperidone, Risperidone, Rufinamide, Temozolomide, Tipranavir, Topiramate, Topiramate, Vorinostat, Zidovudine, Zinc, Zuclopenthixol
PREGNANCY CATEGORY: D
Gestational exposure to valproate is associated with an unacceptably high risk of major congenital malformations, neurodevelopmental disorders, and other adverse outcomes. Prescription of valproate to reproductive-age women is therefore strongly discouraged in many parts of the world.
From January 2024, the United Kingdom began regulating that no one under the age of 55 will be newly prescribed sodium valproate unless two specialists agree that no other effective or tolerable treatment is available, or unless there are "compelling reasons that reproductive risks do not apply" (Medicines and Healthcare Products Regulatory Agency. Date of Issue: 28 November 2023; Reference No: NatPSA/2023/013/MHRA).
See full prescribing information for complete boxed warning.
Please login to see the rest of this drug profile
Page last updated 02/23/2024
Symbol key
Incidence
- <1%
- 1-5%
- 5-10%
- 10-15%
- 15-20%
- 20-30%
- >30%
Warnings in other populations
- Breast feeding
- Geriatric
- Pediatric